Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral small molecule Factor D inhibitors to Alexion’s pipeline and provides the foundation and expertise for a broader oral Factor D inhibition development platform with the potential to treat numerous additional complement-mediated diseases. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines.
Read the full article: Alexion Completes Acquisition of Achillion //
Source: https://www.businesswire.com/news/home/20200128005516/en/Alexion-Completes-Acquisition-Achillion